Key Takeaways

Selank is purported to reduce anxiety while preserving alertness and supporting cognition.
The studies below show why that story is scientifically plausible and why it remains incomplete.
The best human evidence is small, route-specific, and concentrated in Russian-language studies; the best mechanistic evidence is preclinical.
The most accurate summary is that Selank has an investigational anxiolytic signal, not a validated U.S. therapeutic profile.

‍

[Zozulia et al., 2008; Medvedev et al., 2014; Vyunova et al., 2018; FDA, 2026].

Selank acetate / TP-7: an unapproved U.S. investigational tuftsin-derived heptapeptide, canonical sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP), marketed in several acetate forms and registered in Russia as an intranasal diacetate anxiolytic, but not FDA-approved for any indication.

Overview

The central scientific and compliance problem with Selank acetate / TP-7 is not that the molecule has no human history. It does. The problem is evidence transfer across regulatory systems, chemical forms, product presentations, and study designs. A Russian medicinal product is a defined 0.15% intranasal solution of the Selank diacetate form, while U.S. consumer channels use the labels Selank, Selank acetate, TP-7, monoacetate, diacetate, N-acetyl Selank, nasal spray, and injectable vial as though they were one standardized product. They are not. Russian registration does not confer FDA approval, and Russian intranasal product evidence does not automatically validate a U.S. compounded nasal spray or a subcutaneous injection. [Russian Product Information, n.d.; FDA, 2026; PubChem, 2026; NCATS Inxight Drugs, 2026]

The same-molecule human evidence is limited but nonzero. Indexed Russian-language studies include a 62-patient comparison with medazepam in generalized anxiety disorder and neurasthenia, a 60-patient comparison with phenazepam in phobic-anxiety and somatoform disorders, a 70-patient phenazepam-plus-Selank adjunct study, an exploratory cytokine study, and a small healthy-participant functional connectivity study. Those papers are clinically relevant, but they do not amount to a large, independently replicated, multicenter, prospectively registered, double-blind placebo-controlled development program. [Zozulia et al., 2008; Uchakina et al., 2008; Medvedev et al., 2014; Medvedev et al., 2015; Panikratova et al., 2020; ClinicalTrials.gov, 2026]

The mechanistic literature is more developed than the clinical literature. Preclinical work links Selank to inhibition of enkephalin-degrading enzymes, changes in inhibitory synaptic activity, context-dependent effects on GABAergic gene expression and ligand binding, hippocampal BDNF regulation, and immune/cytokine signaling. That map is biologically plausible, but it is not a validated human receptor-level mechanism and does not justify phrases such as "natural Xanax," "GABA-A agonist," "repairs neuroplasticity," or "balances neurotransmitters." [Zozulya et al., 2001; Povarov et al., 2017; Volkova et al., 2016; Filatova et al., 2017; Inozemtseva et al., 2008; Vyunova et al., 2018]

What it is

Selank is a synthetic seven-amino-acid peptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, abbreviated TKPRPGP. It is commonly described as a synthetic analogue of tuftsin, the endogenous tetrapeptide Thr-Lys-Pro-Arg. Selank adds the C-terminal Pro-Gly-Pro tripeptide to that tuftsin-related sequence. The extension changes the molecule; Selank is not simply endogenous tuftsin supplied from outside the body. [Vyunova et al., 2018; PubChem, 2026; NCATS Inxight Drugs, 2026]

The unmodified free peptide is listed by PubChem as C33H57N11O9 with a molecular weight of approximately 751.9 g/mol. The diacetate record is a separate chemical representation with two acetate counterions, formula C37H65N11O13, molecular weight approximately 872.0 g/mol. A commercial research reagent from Cayman is explicitly identified as the monoacetate. [PubChem, 2026; NCATS Inxight Drugs, 2026; Cayman Chemical, 2023]

Those distinctions are not bookkeeping. "Selank acetate" can refer to at least a monoacetate or diacetate presentation, while "N-acetyl Selank" denotes a covalently modified peptide rather than an acetate salt. The Russian medicinal product identifies its active as the diacetate and contains methylparaben plus purified water in a defined nasal-drop presentation. A U.S. vial labeled only "Selank acetate" may not disclose the same stoichiometry, excipients, assay basis, device, or stability package. [Russian Product Information, n.d.; PubChem, 2026; Cayman Chemical, 2023]

Material	What it is	Why it cannot be collapsed into "Selank acetate"
Tuftsin (TKPR)	Endogenous tetrapeptide related to immunoglobulin G processing.	Parent-lineage biology does not prove that exogenous Selank is safe or effective. [Vyunova et al., 2018]
Selank free peptide	Synthetic heptapeptide TKPRPGP.	This is the parent free peptide, not automatically the same API as an acetate salt product. [PubChem, 2026; NCATS Inxight Drugs, 2026]
Selank monoacetate	One acetate counterion; a defined research-reagent form sold by Cayman.	Research-reagent identity and handling instructions do not validate a human drug product. [Cayman Chemical, 2023]
Selank diacetate	Two acetate counterions; the form named in the Russian product information.	Russian product data apply to that defined presentation, not every item called "Selank acetate." [Russian Product Information, n.d.; NCATS Inxight Drugs, 2026]
N-acetyl Selank	Covalently N-acetylated analogue marketed in nootropic channels.	N-acetylation changes the molecule; claims cannot be transferred from native Selank without direct evidence. [PubChem, 2026]
Compounded nasal spray	A pharmacy-prepared pump or drop product whose salt, concentration, device, excipients, and hold time may vary.	It is not automatically equivalent to the Russian labeled drops or to a study preparation. [FDA, 2026; Russian Product Information, n.d.]
Injectable / lyophilized vial	Market presentation intended for reconstitution or research.	No same-route human efficacy or PK package was identified; parenteral use adds sterility, endotoxin, aggregation, and immunogenicity questions. [FDA, 2026]

How it's proposed to work

The best-supported mechanistic backbone begins with peptide-metabolism work rather than a single validated receptor. Zozulya and colleagues reported that Selank inhibited enzymes involved in enkephalin degradation, and mouse work linked behavioral effects with changes in plasma enkephalin-degrading activity. This supports a hypothesis in which Selank alters endogenous regulatory-peptide turnover. It does not establish that a specific enkephalin pathway explains clinical anxiety outcomes in humans. [Zozulya et al., 2001; Sokolov et al., 2002]

The second mechanistic anchor is GABAergic modulation, but the evidence is more qualified than market language suggests. Rat hippocampal slice work reported increased amplitude and discharge rate of spontaneous inhibitory postsynaptic currents after Selank exposure, and a later review summarized radioligand findings as compatible with positive allosteric modulation of GABA-related binding. At the same time, an IMR-32 neuroblastoma study found that Selank alone did not directly change mRNA levels of the assayed GABAergic genes. [Povarov et al., 2017; Filatova et al., 2017; Vyunova et al., 2018]

A third layer comes from transcriptomic and combination studies. Selank altered expression of several neurotransmission-related genes in rat brain and modulated gene-expression responses to GABA or olanzapine in cell systems. In a chronic mild-stress rat model, Selank reduced anxiety-like behavior and changed the effect of diazepam. [Volkova et al., 2016; Filatova et al., 2017; Kasian et al., 2017]

The BDNF story is similarly time- and model-dependent. Intranasal administration in rats changed hippocampal BDNF mRNA and protein at different time points, with increases at some measurements and a decrease at another high-dose early time point. [Inozemtseva et al., 2008; Kolik et al., 2019]

The immune-signaling literature reflects Selank's tuftsin lineage. Human and preclinical papers report changes in cytokine-related measures, and a rat transcriptomic study found time-dependent effects on inflammation-related genes. [Uchakina et al., 2008; Kolomin et al., 2014; Yasenyavskaya et al., 2021]

Common forms in circulation

FDA's current safety-risk page uses the name "Selank acetate (TP-7)" without turning that label into a validated dosage form. Russian regulatory materials describe a different and much more specific object: a 0.15% intranasal drop solution of threonyl-lysyl-prolyl-arginyl-prolyl-glycyl-proline diacetate with methylparaben and purified water, packaged in a 3 mL bottle and registered under number LRS-003338/09. [FDA, 2026; Russian Product Information, n.d.]

U.S. and online channels circulate Selank as pharmacy-compounded nasal sprays, clinic-supplied nasal preparations, lyophilized vials, research kits with nasal applicators, ready-to-use research sprays, and N-acetyl Selank products. These pages document market behavior; they do not establish the identity, sterility, dose uniformity, stability, safety, or clinical validity of the products sold. [Meta Molecule, 2026; American Peptides, 2026; Innerbody, 2026]

Names and aliases

Names to track include Selank, Selanc, TP-7, TP 7, TKPRPGP, threonyl-lysyl-prolyl-arginyl-prolyl-glycyl-proline, Selank acetate, Selank monoacetate, Selank diacetate, and Selank nasal drops or spray. N-acetyl Selank, sometimes called N-Acetyl-Selank or NASA-Selank in commercial channels, is a different covalently modified analogue and should not inherit native-Selank evidence. [PubChem, 2026; NCATS Inxight Drugs, 2026; Cayman Chemical, 2023]

The most common pairing is Semax plus Selank, marketed as a complementary "focus and calm" or "productive calm" protocol. Other pairings include DSIP for sleep, noopept, cerebrolysin, oxytocin, racetams, stimulant or ADHD programs, and conventional antidepressant or anxiolytic therapy. These pairings reflect market logic, not controlled combination evidence. [YoungerMeMD, 2026; Pure Bio Labs, 2026; KlearMind Clinics, 2026]

Regulatory status

No FDA-approved Selank product or human indication was identified. Selank is not an approved treatment for generalized anxiety disorder, panic, neurasthenia, depression, ADHD, cognitive impairment, sleep disorders, stress, or any wellness use in the United States. [FDA, 2025; FDA, 2026]

FDA's current "Certain Bulk Drug Substances" page places Selank acetate (TP-7) in the section for bulk drug substances nominated but withdrawn. FDA states that compounded drugs containing Selank acetate may pose immunogenicity risk for certain routes because of potential aggregation and peptide-related impurities, and that the agency lacks important information about safety issues raised by Selank acetate administered to humans. [FDA, 2026]

The May 14, 2026 503A category document lists active Category 1, 2, and 3 substances. Selank is absent from those active tables. Its appearance in a separate withdrawn-nomination section means the nomination process ended procedurally; it does not place Selank on the 503A bulks list, convert it to Category 1, resolve the safety concerns, or authorize broad compounding. [FDA, 2026]

In a 2020 warning letter to Tailor Made Compounding, FDA named Selank among bulk substances used in products that did not satisfy section 503A conditions and documented serious deficiencies in sterile production. [FDA, 2020]

Russia presents a separate regulatory system and a separate product. The reviewed Russian product information lists Selank intranasal drops as an anxiolytic/tranquilizer under ATC code N05BX and provides indications, contraindications, adverse effects, packaging, and storage conditions. It is accurate to say that a defined Selank diacetate intranasal product is registered in Russia. It is not accurate to translate that into "FDA-approved," "internationally approved," or "approved for compounded injection." [Russian Product Information, n.d.; FDA, 2026]

FDA and the Federal Register identify seven peptide-related substances for the July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting: BPC-157, KPV, TB-500, MOTS-C, emideltide/DSIP, Semax, and Epitalon. Selank is not listed. [FDA, 2026; Federal Register, 2026]

Safety

Human therapeutic safety is incompletely characterized. The Russian product information lists unpleasant taste if liquid reaches the pharynx and possible allergic reactions, and it advises against use in pregnancy, lactation, and patients under 18 because efficacy and safety were not studied in those groups. The label also states that dependence, habituation, overdose cases, and clinically relevant interactions were not observed under its experience. Those are product-label assertions, not a substitute for independently replicated, long-term, internationally reported safety data. [Russian Product Information, n.d.]

The indexed human studies are too small and too narrowly reported to define uncommon adverse events, withdrawal risk, reproductive safety, pediatric or geriatric safety, interaction risk, long-term psychiatric outcomes, or the safety of repeated courses. [Zozulia et al., 2008; Medvedev et al., 2014; Medvedev et al., 2015]

For intranasal use, the most immediate safety domains are local irritation, epistaxis, altered smell or taste, allergy, contamination after opening, and inconsistent delivery. For parenteral use, the domains broaden to injection-site reactions, infection, endotoxin exposure, particulates, hypersensitivity, aggregates, and immunogenicity. [FDA, 2026; Russian Product Information, n.d.]

Purported benefits, by evidence strength

Purported benefit	Tagged evidence strength	What the evidence supports	What it does not support
Anxiety symptom reduction	Limited human active-comparator evidence	Small Russian studies reported anxiolytic effects in generalized anxiety/neurasthenia and phobic-anxiety/somatoform populations compared with medazepam or phenazepam.	Does not support "clinically proven for anxiety," superiority to standard care, U.S. product equivalence, or efficacy by injection. [Zozulia et al., 2008; Medvedev et al., 2014]
Neurasthenia / asthenic symptoms	Limited human comparator evidence	The 2008 study included neurasthenia and reported antiasthenic or activating signals alongside anxiolysis.	Does not support treatment claims for chronic fatigue, burnout, depression, or nonspecific low energy. [Zozulia et al., 2008]
Calm without sedation	Human comparator signal plus label claim	Human papers and the Russian label describe anxiolysis with less emphasis on sedation than benzodiazepine comparators.	Does not support "non-sedating," "safe to drive," "no impairment," or "better than benzodiazepines" as universal claims. [Russian Product Information, n.d.; Medvedev et al., 2014]
Cognitive support / focus / memory	Animal model; limited secondary human signal	Rat learning studies and human comparator papers reported mild nootropic or cognitive-associated findings.	Does not support cognitive enhancement in healthy adults, ADHD treatment, improved executive function, or durable memory gains. [Kozlovskii and Danchev, 2003; Medvedev et al., 2014]
Stress resilience / adaptive behavior	Animal model and label framing	Rodent stress paradigms and Russian product language support an experimental stress-adaptation narrative.	Does not support "switches off stress," lowers cortisol in patients, prevents burnout, or protects against trauma. [Kozlovskaya et al., 2003; Russian Product Information, n.d.]
GABAergic calming	Mechanistic hypothesis	Electrophysiology, binding, and gene-expression work is compatible with modulation of inhibitory signaling.	Does not support "GABA-A agonist," "positive allosteric modulator in humans," "natural Xanax," or a validated receptor mechanism. [Povarov et al., 2017; Filatova et al., 2017; Vyunova et al., 2018]
BDNF / neuroplasticity support	Animal model and mechanistic hypothesis	Intranasal rat work reported time-dependent hippocampal BDNF mRNA and protein changes.	Does not support "boosts BDNF," repairs neuroplasticity, neuroregeneration, antidepressant efficacy, or dementia prevention in humans. [Inozemtseva et al., 2008]
Immune modulation / inflammatory balance	Human exploratory and preclinical	Exploratory patient cytokine work and animal transcriptomics reported immune-signaling changes.	Does not support "boosts immunity," reduces neuroinflammation, treats autoimmune disease, or prevents infection. [Uchakina et al., 2008; Kolomin et al., 2014]
Sleep and mood stabilization	Label claim and commercial extrapolation	Russian product information includes sleep disturbance and mood instability among labeled anxiety-state symptoms.	Does not support insomnia treatment, antidepressant efficacy, bipolar stabilization, or a general sleep-aid claim in the United States. [Russian Product Information, n.d.; FDA, 2026]
Benzodiazepine-sparing or adjunct synergy	Human adjunct study and animal combination work	A 70-patient study evaluated Selank added to phenazepam; rat work explored interaction with diazepam.	Does not support established synergy, routine dose reduction, withdrawal prevention, safer tapering, or broad compatibility with psychoactive drugs. [Medvedev et al., 2015; Kasian et al., 2017]

Key literature

Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. A 62-patient study: Selank in 30 patients was compared with medazepam in 32 patients using anxiety and global measures.

Medvedev VE, Tereshchenko ON, Israelian AIu, et al. A comparison of the anxiolytic effect and tolerability of Selank and phenazepam in treatment of anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(7):17-22. A 60-patient study reporting anxiolytic, mild nootropic, quality-of-life, and tolerability signals versus phenazepam.

Medvedev VE, Tereshchenko ON, Kost NV, et al. Optimization of the treatment of anxiety disorders with Selank. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(6):33-40. A 70-patient adjunct study evaluating phenazepam alone versus phenazepam plus Selank.

Panikratova YR, Lebedeva IS, Sokolov OY, et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Dokl Biol Sci. 2020;490(1):9-11. Short-term functional connectivity changes after Selank, Semax, or placebo in 52 healthy participants.

Povarov IS, Kondratenko RV, Derevyagin VI, Myasoedov NF, Skrebitsky VG. Effect of Selank on Spontaneous Synaptic Activity of Rat Hippocampal CA1 Neurons. Bull Exp Biol Med. 2017;162(5):640-642. Increased amplitude and discharge rate of inhibitory postsynaptic currents in hippocampal slices.

Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein Pept Lett. 2018;25(10):914-923. Review synthesizing sequence, tuftsin lineage, GABA-related, peptide-metabolism, gene-expression, and behavioral literature.

References

FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current April 22, 2026.
FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Updated May 14, 2026.
FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Updated June 29, 2026.
FDA. Tailor Made Compounding LLC - Warning Letter 594743. April 1, 2020.
Federal Register. Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments. 2026;91 FR. Published April 16, 2026.
Peptogen / Selank. Instructions for Medical Use of Selank, registration number LRS-003338/09; Russian-language product information.
PubChem. Selank. CID 11765600. Accessed July 14, 2026.
World Anti-Doping Agency. 2026 Prohibited List, effective January 1, 2026.

Selank Acetate TP-7